KL2 Visiting Scholar Grand Rounds - Dr. Shane Stecklein

Presenter: Shane Stecklein, M.D., Ph.D., University of Kansas

March 23, 2022
8 a.m. to 9 a.m.

Join Meeting: https://ohsu.webex.com/ohsu/j.php?MTID=mb3140c5c063e7f3acb3c180327c1240d
Meeting password: chmwebex1

Phone (audio only):
1-206-207-1700 US
1-503-907-9144 Portland, OR
Meeting number (access code): 120 493 6238

Contact Information
Melissa Mudd

Grand Rounds details

Shane Stecklein headshot

Join us in welcoming OHSU KL2 visiting scholar: Shane Stecklein, M.D., Ph.D., Assistant Professor of Radiation Oncology at the University of Kansas

Grand Rounds topic: Molecular Determinants of Response to Chemoimmunotherapy in Triple-Negative Breast Cancer

About the presenter:
Dr. Stecklein is an Assistant Professor of Radiation Oncology at The University of Kansas School of Medicine and The University of Kansas Cancer Center, and he serves as the Director of Translational Research for Radiation Oncology. He specializes in the treatment of breast cancer and lymphoma/myeloma. In addition to his primary appointment in Radiation Oncology, Dr. Stecklein holds joint appointments as Assistant Professor in the Department of Pathology & Laboratory Medicine and the Department of Cancer Biology. He leads a basic-translational research laboratory that aims to understand the molecular pathogenesis of triple-negative breast cancer (TNBC) and the interplay between genomic instability, the tumor microenvironment, and response to therapy in TNBC. Dr. Stecklein uses a combination of in vitro and in vivo molecular, genetic, and computational approaches to work towards his long-term goals of defining and optimizing personalized treatment strategies for TNBC and translating promising pre-clinical findings into early-stage therapeutic trials.
Learn more about Dr. Stecklein and his research interests.

OCTRI's KL2 Program is designed to support early-career faculty in their transition to research independence. The mission of the KL2 award is to identify and support promising faculty who may benefit from OCTRI support and resources in their efforts to obtain independent research funding. The KL2 award is funded by the NIH National Center for Advancing Translational Research (NCATS) through the Clinical Translational Science Award program, which supports a national network of research institutions. The KL2 Visiting Scholars Program was developed by CTSA consortium partners to promote collaborative cross-CTSA training, leverage academic strengths at host CTSAs, and support the career development of participating scholars through experiential training and the development of new partnerships. 

*CMEs are offered for this ground rounds through the Knight Cancer Hematology/Oncology Division. Please contact Kathy Beebe beebek@ohsu.edu with questions regarding CME credits.

If you have a disability and need an accommodation to attend or participate in this event, please contact Melissa Mudd muddm@ohsu.edu at least five business days before the event.